Special Drug Use Investigation for PAXIL Tablet (Investigation in Case of Administered From 20mg/Day)

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Panic Disorder

Treatments: Drug: Paroxetine

Study type: Observational

Funder types: Industry

Identifiers

NCT01371474

112308

Details and patient eligibility

About

The objective of this survey was to understand the safety and efficacy of PAXIL tablets ("PAXIL", hereinafter) when it was started at 20 mg/day in subjects with depression or in a depressed state.

Enrollment: 1,483 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with depression or in a depressed state
• Patients who start taking paroxetine at 20mg a day

Exclusion criteria

• Patients who have been treated with paroxetine prior to this investigation
• Patients with hypersensitivity to paroxetine
• Patients taking monoamine oxidase inhibitors (MAOIs) or within 2 weeks of stopping treatment with MAOIs
• Concomitant use in patients taking pimozide

Trial design

1,483 participants in 1 patient group

Patients prescribed PAXIL

Description:

Patients with depression or in a depressed state starting PAXIL at 20 mg/day during study period

Treatment:

Drug: Paroxetine